May 2013 | Targeted Therapies in Oncology

Biomarkers Still Needed in Prostate Cancer

May 21, 2013

Clinical Articles

Although biomarkers have been shown to correlate with survival in prostate cancer, the use of biomarkers in the management of these patients may be dependent upon the clinical state and the class of drug evaluated.

New Developments in Oral Targeted Agents for Advanced Colorectal Cancer

May 20, 2013

Clinical Articles

In September 2012, the FDA approved regorafenib as a salvage treatment for metastatic colorectal cancer (mCRC) previously treated with chemotherapy, an antivascular endothelial growth factor therapy, or an anti-EGFR therapy.

A Guide to ASCO 2013: Key Targeted Trials

May 14, 2013

Clinical Articles

In advance of the 2013 American Society of Clinical Oncology annual meeting, Targeted Therapy News spoke with this year’s chair of the Scientific Program Committee, Douglas Yee, MD, about key presentations and sessions that attendees can expect.